Bionomics signs $US506m deal with Merck to fund Alzheimer’s research
Biotech firm Bionomics has partnered with American pharmaceutical company Merck to fund research into Alzheimer’s disease and other central nervous system conditions.
Biotech firm Bionomics has partnered with American pharmaceutical company Merck to fund research into Alzheimer’s disease and other central nervous system conditions.
Merck has agreed to pay an upfront sum of $US20 million ($21.2 million), and Bionomics could receive up to $US506 million ($537 million) if it hits certain research and development targets.
